AUTHOR INDEX

(S = supplement; P = proceedings)

AARONS, L. *see* TOONS, S.
ABATZI, Th.-A. *see* STACHER, G.
ACTON, G. *see* EAGLE, S.
ADAMS, J. *see* ROLAN, P.E.
ADAMS, M. *see* LENNARD, M.S.
ADAMS, P.C. *see* WYNNE, H.A.
ADVENIER, C. *see* NALINE, E.
AL-AZAWIE, D.M. *see* WEBB, A.J.
AL-LANQAWI, Y., MORELAND, T.A., MCEWEN, J., HALLIDAY, F., DURNIN, C.J. & STEVENSON, Error in back-extrapolation for estimation of blood alcohol concentration, 333P
AL-SHAREEF, A., BUSS, D.C., SHETTY, H. G. M., ALI, N. & ROUTLEDGE, P. A. The effect of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate on healthy volunteers, 331P
ALI, N. *see* AL-SHAREEF, A.
ALM, C. *see* DAHL-PUUSTINEN, M.-L.
ALVAN, G. *see* GUDJONSSON, O.
ALVAREZ, F. *see* JACQZ-AIGRAIN, E.
AMODIO, P. *see* MERKEL, C.
ANDERER, P. *see* SALETU, B.
ANDREASEN, F. *see* SONNE, J.
ANGELI, P. *see* MERKEL, C.
ANGELO, H.R. *see* HERRSTEDT, J.
ANTHONY, L.B. *see* ZHOU, H.H.
ANTTILA, M. *see* KARHUVA, S.
AQUILONIUS, S.-M. *see* GUDJONSSON, O.
ARANKO, K. *see* KUITUNEN, T.
ARENDT-NIELSEN, L. *see* NIELSEN, J.C.
ARIAS, T.D. *see* JORGE, L.F.
ARNOLD, B.D.C. *see* WEBB, A.J.
ARONSON, J.K. *see* WOOD, A.J.
AZULAY, J.P. *see* BLIN, O.

BACK, D.J. *see* CRAWFORD, P.
BACK, D.J. *see* SIM, S.M.
BACK, D.J. *see* TIJA, J.F.
BACK, D.J., TIJA, J.F., HOULGRAVE, R. & M.L'E. ORME Effect of progestogens on the metabolism of ethinyloestradiol by human liver microsomes *in vitro*, 321P
BADOER, E. *see* UNGER, TH.
BAESE, C. *see* MONIG, H.
BAGHERI, H., BERLAN, M., MONTASTRUC, J.L. & MONTASTRUC, P. Yohimbine and lacrimal secretion, 151
BAILEY, R.R. *see* BEGG, E.J.
BAILS, M. *see* GENEVE, J.
BAKES, A., BRADSHAW, C.M. & SZABADI, E., Attenuation of the pupillary light reflex in anxious patients, 377
BALFOUR, D.J.K. *see* LANG, C.C.
BARNETT, D.B. *see* SCOTT, R.A.
BARROW, S.E. *see* MINUZ, P.
BASSANI, C. *see* MARASINI, B.
BATEMAN, D.N. *see* RASHID, M.U.
BAUMGARTNER, H., HORTNAGL, H., LUCKE, G., STRIESSENIG, J., WIEDERMANN, C.J. & HOCHLEITNER, G. Vasodepressor syncope and cathecholamine response, 337P
BEAUMONT, D. *see* REY, E.
BECK-NIELSEN, H. *see* SINDRUP, S.H.
BEDFORD, D.K. *see* SERIES, J.J.
BEEMANN, D. *see* HARDER, S.
BEGG, E.J., ROBSON, R.A., BAILEY, R.R., LYNN, K.L., FRANK, G.J. & OLSON, S.C. The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment, 213
BEHAN, P.O. *see* BOYLE, R.
BELL, P. *see* KING, D.J.
BELLON, S. *see* MERKEL, C.
BENGTSSON, M. *see* CEDERHOLM, I.
BENOVIC, J.L., ONORATO, J., LOHSE, M.J., DOHLMAN, H.G., STANISZEWSKI, C., CARON, M.G. & LEFKOWITZ, R.J. Synthetic peptides of the hamster β_2-adrenoceptor as substrates and inhibitors of the β_2-adrenoceptor kinase, 3S
BENSIMON, G., FORET, J., WAROT, D., LACOMBLEZ, L., THIERCELIN, J.F. & SIMON, P. Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo, 463
BERGMANN, H. *see* STACHER, G.
BERLAN, M. *see* BAGHERI, H.
BERLIN, I., ZIMMER, R., THIEDE, H.-M., PAYAN, C., HERGUETA, T., ROBIN, L. & PUECH, A.J. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on pyschometric performance in healthy subjects, 805
BERTILSSON, L. *see* DAHL-PUUSTINEN, M.-L.
BEST, S.J. *see* KING, D.J.
BETTERIDGE, D.J. *see* WALDEN, R.J.
BEVAN, E.G., WALLER, P.C., HERRICK, A.L., PRINGLE, S.D., FINDLAY, J.G., MURRAY, G.D., CARMICHAEL, H.A., REID, J.L., LORIMER, A.R. & MCINNES, G.T. Comparison of captopril, hydralazine and nifedipine as third drug in hypertensive patients, 305P
BIANCHETTI, G. *see* WEBER, S.
BINDER, A. *see* STACHER, G.
BIRNBAUMER, L., YATANI, A., VANDONGEN, A.M.J., GRAF, R., CODINA, J., OKABE, K., MATTERA, R. & BROWN, A.M. G protein coupling of receptors to ionic channels and other systems, 13S
BJERRING, P. *see* NIELSEN, J.C.
BJORKMAN, S. *see* CEDERHOLM I.
BLAUW, G.J. *see* VAN ZWIETEN, P.A.
BLIN, O., MASSON, G., AZULAY, J.P., FONDARAI, J. & SERRATRICE, G. Apomorphine-induced blinking and yawning in healthy volunteers, 769
BOESGAARD, S. *see* SONNE, J.
BOGAERT, M.G. *see* LEFEBVRE, R.A.
BOLOGNESI, M. *see* MERKEL, C.

BOOBIS, A.R. & DAVIES, D.S. Debrisoquine oxidation phenotype and susceptibility to lung cancer, 654
BORTON, M., NELIGAN, M., WOOD, F., DERVAN, P., GOGGINS, K. & DOCHERTY, J.R. Contractions to 5-hydroxytyptamine in human coronary artery and human saphenous vein, 107S
BOSSINI, A., DI VEROLI, C., CAVALLOTTI, G. & CAGLI, V. Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo, 567
BOSTON, V. *see* WOOLFSON, A.D.
BOWES, S.G., CLARK, P.K., LEEMAN, A.L., O'NEILL, C.J.A., WELLER, C., NICHOLSON, P.W., DESHMUKH, A.A., DOBBS, S.M. & DOBBS, R.J. Determinants of gait in the elderly Parkinsonian on maintenance levodopa/carbidopa therapy, 13
BOYLE, R., BEHAN, P.O. & SUTTON, J.A. A correlation between severity of migraine and delayed gastric emptying measures by an epigastric impedance method, 405
BRADSHAW, C.M. *see* BAKES, A.
BRADSHAW, C.M. *see* MORLEY, M.J.
BRAIN, S.D., PETTY, R.G., LEWIS, J.D. & WILLIAMS, T.J. Cutaneous blood flow responses in the forearms of Raynaud's patients induced by local cooling and intradermal injections of CGRP and histamine, 853
BREARLEY, C.J. *see* WOOD, A.J.
BRECKENRIDGE, A.M. *see* COLEMAN, M.D.
BRECKENRIDGE, A.M. *see* HELSBY, N.A.
BRECKENRIDGE, A.M. *see* SCOTT, A.K.
BREDESEN, J.E. *see* MATHESON, I.
BREIMER, D.D. *see* VAN STEVENINCK, A.L.
BRENNEISEN, R., FISCH, H.-U., KOELBING, U., GEISSHUSLER, S. & KALIX, P. Amphetamine-like effects in humans of the khat alkaloid cathinine, 825
BRICKL, R. *see* MULLER, T.H.
BROCKWAY, M. *see* TIPLADY, R.
BRODDE, O.-E. *see* MICHEL, M.C.
BRODDE, O.-E. *see* MOTOMURA, S.
BRODDE, O.-E., REID, J.L. & VAN ZWIETEN, P.A. Introduction, 1S
BRODDE, O.-E. *see* VAN TITS, L.J.H.
BROOM, C. *see* EAGLE, S.
BROSEN, K. *see* SINDRUP, S.H.
BROUARD, A. *see* GENEVE, J.
BROWN, A.M. *see* BIRNBAUMER, L.
BROWN, J. *see* JEFFREY, R.F.
BUHLER, F.R. *see* JONES, C.R.
BULLINGHAM, R. *see* TOON, S.
BULPITT, C. *see* PALMER, A.
BULPITT, C.J. & FLETCHER, A.E. The measurement of quality of life in hypertensive patients: a practical approach, 353
BUNNAG, D. *see* NOSTEN, F.
BUSS, D.C. *see* AL-SHAREEF, A.

CABEZA, D. *see* MORLANS, M.
CAGLI, V. *see* BOSSINI, A.
CALLENDER, J.S. Assessment of quality of life in the treatment of hypertension, 351
CALLENS-EL AMRANI, F. *see* MANSIER, P.
CALZETTI, S. *see* MARTINEZ, C.
CAMPBELL, G.A. *see* MORGAN, D.J.
CAMPBELL, N.R.C., RANKINE, D., GOODRIDGE, A.E., HASINOFF, B.B. & KARA, M. Sinemet-ferrous sulphate interaction in patients with Parkinson's disease, 599
CAPEWELL, S. *see* JEFFREY, R.F.
CAPORASO, N. & IDLE, J.R. The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs *et al.*, 1990), 149
CAPPIELLO, E. *see* CASTEL, J.M.
CARMICHAEL, H.A. *see* BEVAN, E.G.
CARON, M.G. *see* BENOVIC, J.L.
CARRAI, M. *see* PACIFICI, G.M.
CARRUTHERS, S.G. *see* DANTER, W.R.
CASTEL, J.M., CAPPIELLO, E., LEOPALDI, D. & LATINI, R. Rifampicin lowers plasma concentrations of propafenone and its antiarrhythmic effect, 155
CAULIN, C. *see* GENEVE, J.
CAVALLOTTI, G. *see* BOSSINI, A.
CEDERHOLM, I., BENGTSSON, M., BJORKMAN, S., CHOONARA, I. & RANE, A. Long term high dose morphine, ketamine and midazolam infusion in a child with burns, 901
CERNY, T. *see* LIND, M.J.
CHADWICK, D.J. *see* CRAWFORD, P.
CHARLEMAGNE, D. *see* MANSIER, P.
CHAUHAN, B.L. *see* DOSHI, B.S.
CHEN, X. *see* WESTFALL, T.C.
CHEUNG, R., CLARK, P., NICHOLSON, P.W., DESHMUKH, A.A., O'NEILL, C.J.A., DOBBS, S.M. & DOBBS, R.J. Screening for aminoglycoside auditory toxicity in the old, 1
CHEVALIER, B. *see* MANSIER, P.
CHIRON, C. *see* REY, E.
CHOLERTON, S. *see* EDWARDS, C.
CHOONARA, I. *see* CEDERHOLM, I.
CHOONARA, I., EKBOM, Y., LINDSTROM, B. & RANE, A. Morphine sulphation in children, 897
CHOY, A.M. *see* LANG, C.C.
CHRISTESON, I. *see* DAHL-PUUSTINEN, M.-L.
CHURCH, M.K. *see* NG, W.H.
CIARLEGLIO, A. *see* WESTFALL, T.C.
CLARK, P. *see* CHEUNG, R.
CLARK, P.K. *see* BOWES, S.G.
COCKCROFT, J.R. *see* MINUZ, P.
CODINA, J. *see* BIRNBAUMER, L.
COHEN, A.F. *see* VAN STEVENINCK, A.L.
COLE, L., HANNING, C.D., ROBERTSON, S. & QUINN, K. Further development of a morphine hydrogel suppository, 781
COLEMAN, M.D. *see* RILEY, R.J.
COLEMAN, M.D., SCOTT, A.K., BRECKENRIDGE, A.M. & PARK, B.K. The use of cimetidine as a selective inhibitor of dapsone *N*-hydroxylation in man, 761
COLEMAN, M.D. *see* TINGLE, M.D.
COLLIER, A. *see* JEFFREY, R.F.
CONNACHER, A.A., LAKIE, M., POWERS, N., ELTON R.A., WALSH, E.G. & JUNG, R.T. Tremor and anti-obesity drug BRL 26830A, 613
COOPER, S.M. *see* MCCLELLAND, G.R.
COOPER, S.M. *see* WEBB, A.J.
CORMIE, P. *see* MULLOY, E.M.

COUET, W., ISTIN, B., DECOURT, J.P., INGRAND, I., GIRAULT, J. & FOURTILLAN, J.B. Lack of effect of ponsinomycin on the pharmacokinetics of nicoumalone enantiomers, 616
COURNOT, A. *see* RAGHOEBAR, M.
COUTIE, W.J. *see* LANG, C.C.
COUTIE, W.J.K. *see* LANG, C.C.
CRANKSHAW, D.P. *see* MORGAN, D.J.
CRAWFORD, P., CHADWICK, D.J., MARTIN, C., TIJA, J., BACK, D.J. & ORME, M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids, 892
CRAWFORD, V.L.S. *see* PASSMORE, A.P.
CRUICKSHANK, J.M. *see* TOMLINSON, B.
CURRIE, D. *see* NICHOLSON, A.N.
CURRIE, D., LEWIS, R.V., MCDEVITT, D.G., NICHOLSON, A.N. & WRIGHT, N.A. Central effects of the angiotensin-converting enzyme inhibitor, captopril. I Performance and subjective assessments of mood, 527
CUTLER, R.E. *see* KASMER, R.J.

D'ATHIS, Ph. *see* REY, E.
DAHL-PUUSTINEN, M.-L., ALM, C., BERTILSSON, L., CHRISTESON, I., OSTMAN, J., THUNBERG, E. & WIKSTROM, I. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes, 476
DAHLQVIST, R. *see* LINDHOLM, A.
DANTER, W.R. & CARRUTHERS, S.G. The heart rate-PR interval relationship: a model for evaluating drug actions on SA and AV nodal function, 490
DARGIE, H.J. *see* MURDOCH, D.L.
DAUL, A. *see* VAN TITS, L.J.H.
DAVIES, B.E. *see* WEBB, A.J.
DAVIES, D.S. *see* BOOBIS, A.R.
DAVIES, I.B. *see* SINCLAIR, A.J.
DAVIS, T.M.E., KARBWANG, J., LOOAREESUWAN, S., TURNER, R.C. & WHITE, N.J. Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers, 397
DAY, R.O. *see* JOYCE, D.A.
DE LAUTURE, D. *see* WEBER, S.
DE MEY, C. *see* EAGLE, S.
DE MEY, C. *see* HIEBLE, J.P.
DE PONT, J.J.H.H.M. *see* GRAAFSMA, S.J.
DECOURT, J.P. *see* COUET, W.
DEFOIN, R. *see* HARTMANN, D.
DEIGHTON, N.M. *see* MACGILCHRIST, A.J.
DEIGHTON, N.M. *see* MOTOMURA, S.
DEL VALLE, K. *see* WESTFALL, T.C.
DERVAN, P. *see* BORTON, M.
DESHMUKH, A.A. *see* BOWES, S.G.
DESHMUKH, A.A. *see* CHEUNG, R.
DESSAULT, O. *see* WEBER, S.
DEWS, I. *see* POTTER, C.
DEWS, I. *see* VANDENBURG, M.
DI VEROLI, C. *see* BOSSINI, A.
DISTLER, A. *see* FRITSCHKA, E.
DIXON, C.M.S. & IND, P.W. Inhaled sodium metabisulphite induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate, 371
DOBBS, N.A., SUMMERS, L.A. & TWELVES, C.J. Measurement of epidoxorubicin and its metabolites by h.p.l.c. and advanced automated sample processor (AASP) in patients with abnormal liver biochemistry, 324P
DOBBS, R.J. *see* BOWES, S.G.
DOBBS, R.J. *see* CHEUNG, R.
DOCHERTY, J.R. *see* BORTON, M.
DOHLMSN, H.G. *see* BENOVIC, J.L.
DOLLERY, C.T. *see* WARREN, J.B.
DOMINGUEZ-GIL, A. *see* FERNANDEZ DE GATTA, M.M.
DONNELLY, R., ELLIOTT, H.L., MEREDITH, P.A. & REID, J.L. Clinical studies with cromakalim in normotensive and hypertensive subjects, 314P
DORAN, J.F. *see* MCDERMID, G.
DOSHI, B.S., KULKARNI, R.D., CHAUHAN B.L. & WILKINSON, G.R. Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population, 779
DOSSING, M. *see* SONNE, J.
DUBOIS, J.P. *see* LECAILLON, J.B.
DUBOIS, J.P. *see* LEFEBVRE, R.A.
DULAC, O. *see* REY, E.
DUNDEE, J.W. Fantasies during benzodiazepine sedation in women, 311P
DUNDEE, J.W. *see* YANG, J.
DUPONT, A.G. *see* SCHOORS, D.F.
DUPONT, A.G. *see* VERCRUYSSE I.
DURNIN, C.J. *see* AL-LANQAWI, Y.

EAGLE, S., ACTON, G., MANCHEE, K., MEINEKE, I., DE MEY, C. & BROOM, C. Relative bioavailability of a novel nifedipine sublingual spray in comparison with a sublingual capsule, 331P
EDEN, R.J. *see* HIEBLE, J.P.
EDSTEIN, M.D., RIECKMANN, K.H. & VEENENDAAL, J.R. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprimx) in man, 259
EDWARDS, C., MONKMAN, S., CHOLERTON, S., RAWLINS, M.D., IDLE, J.R. & FERNER R.E. Lack of effect of co-trimoxazole on the pharmacokinetics and pharmacodynamics of nifedipine, 889
EDWARDS, G. *see* HELSBY, N.A.
EDWARDS, T.J. *see* HAWTHORNE, A.B.
EISERT, W.G. *see* MULLER, T.H.
EKBOM, Y. *see* CHOONARA, I.
EKLUND, A. *see* HJEMDAHL, P.
ELLIOTT, C. *see* SCIBERRAS, D.G.
ELLIOTT, H.L. *see* DONNELLY, R.
ELLIOTT, H.L. *see* SCHAFERS, R.F.
ELTON, R.A. *see* CONNACHER, A.A.
ENDOH, M., OTOMO, J. & NOROTA, I. Phorbol-12,13-dibutyrate antagonizes the α_1-adrenoceptor-mediated positive inotropic effect in the rabbit ventricular myocardium, 115S
EGHUSEN POULSEN, H. *see* SONNE, J.
ERNST, E. Is homoepathy a placebo?, 173
ERTZBISCHOFF, O. *see* NALINE, E.

FAGAN, D. *see* TIPLADY, R.
FANDELEUR, P. *see* JONES, C.R.
FARISH, S. *see* SILAGY, C.A.
FEELY, M. *see* HARDY, E.
FEELY, M. *see* PULLAR, T.

FELDMAN, R.D. β-adrenoceptor responsiveness in hypertension:effects of dietary NaCl intake, 55S
FERNANDEZ DE GATTA, M.M., GALINDO, P., REY, F., GUTIERREZ, J., TAMAYO, M., GARCIA, M.J. & DOMINGUEZ-GIL, A. The influence of clinical and pharmacological factors on enuresis treatment with imipramine, 693
FERNER, R.E. *see* EDWARDS, C.
FILIPOWICZ, B.L. *see* HAWTHORNE, A.B.
FINDLAY, J.G. *see* BEVAN, E.G.
FINUCCI, G.F. *see* MERKEL, C.
FISCH, H.-U. *see* BRENNEISEN, R.
FITZGERALD, D.L. *see* LEWIS, L.D.
FLETCHER, A. *see* PALMER, A.
FLETCHER, A.E. *see* BULPITT, C.J.
FOALE, R.A. & VANDENBERG, M.J. Sustained-release verapamil and nifedipine in exercise-induced angina pectoris, 313P
FOLKERTS, G., JANSSEN, M. & NIJKAMP, F.P. Parainfluenza-3 induced hyperreactivity of the guinea pig trachea coincides with an increase number of broncho-alveolar cells, 159S
FONDARAI, J. *see* BLIN, O.
FORET, J. *see* BENSIMON, G.
FORSYTH, D.R. & ROBERTS, C.J.C. Nitrendipine and the humoural control of sodium homeostasis, 585
FOSTER, G. *see* YEO, W.W.
FOSTER, G., YEO, W.W. & RAMSAY, L.E. Effects of sulindac on the cough reflex of healthy subjects, 327P
FOUKARIDIS, G.N. *see* JOUBERT, P.H.
FOURTILLAN, J.B. *see* COUET, W.
FOWLER, P.A. *see* SCOTT, A.K.
FRACHI, M. *see* PACIFICI, G.M.
FRANK, G.J. *see* BEGG, E.J.
FREY, R. *see* SALETU, B.
FRITSCHKA, E., NEUMAYER, H.-H., SEDDIGHI, S., THIEDE, H.-M., DISTLER, A. & PHILIPP, Th. Effect of erythropoietin on parameters of sympathetic nervous activity in patients undergoing chronic haemodialysis, 135S
FUHR, U. *see* HARDER, S.
FUNCK-BRENTANO, C., SILBERSTEIN, D.J., RODEN, D.M., WOOD, A.J.J. & WOOSLEY, R.L. A mechanism of D-(+)-sotalol effects on heart rate not related to β-adrenoceptor antagonism, 195

GAILLOT, J. *see* MATHESON, I.
GALINDO, P. *see* FERNANDEZ DE GATTA, M.M.
GARCIA, M.J. *see* FERNANDEZ DE GATTA, M.M.
GAREIS, C. *see* UNGER, TH.
GARSSEN, J., VAN LOVEREN, H., VAN DER VLEIT, H. & NIJKAMP, F.P. T cell mediated induction of bronchial hyperreactivity, 153S
GATTA, A. *see* MERKEL, C.
GATTI, G. *see* MARTINEZ, C.
GAUPMANN, G. *see* STACHER, G.
GAW, A. *see* SERIES, J.J.
GEISSHUSLER, S. *see* BRENNEISEN, R.
GEMEINHARDT, A. *see* UNSELD, E.
GENEVE, J., LE DINH, T., BROUARD, A., BAILS, M., SEGRESTAA, J.M. & CAULIN, C. Changes in indocyanine green kinetics after the administration of enalapril to healthy subjects, 297
GIBB, L.A. *see* LANG, C.C.
GIBBS, J. *see* VANDENBURG, M.
GIERSCHIK, P. *see* REITHMANN, C.
GILL, S.S. *see* REILLY, C.S.
GILLAM, E.M.J. *see* OTTON, S.V.
GINGER, C.D. *see* LECAILLON, J.B.
GIOKOGLU, K. *see* WOODCOCK, B.G.
GIRAULT, J. *see* COUET, W.
GIRBES, A.R.J., SMIT, A.J., MEIJER, S. & REITSMA, W.D. Lithium and renal response to gludopa, fenoldopam and dopamine, 652
GIRCHEV, R. *see* UNGER, TH.
GOGGINS, K. *see* BORTON, M.
GOLDBERG, M. *see* WARREN, J.B.
GOLDBERG, M.R. *see* SCIBERRAS, D.G.
GOLDBERG, P. *see* KASMER, R.J.
GOODRIDGE, A.E. *see* CAMPBELL, N.R.C.
GOUDEVENOS, J. *see* WYNNE, H.A.
GRAAFSMA, S.J., HECTORS, M.P.C., VAN TITS, L.J.H., RODRIGUES DE MIRANDA, J.F. & THEIN, TH. The relationship between adrenaline and β_2-adrenoceptors on human lymphocytes, 145S
GRAAFSMA, S.J., VAN TITS, L.J.H., WILLEMS, P.H.G.M., HECTORS, M.P.C., RODRIGUES DE MIRANDA, J.F., DE PONT, J.J.H.H.M. & THEIN, TH. β_2-adrenoceptor up-regulation in relation to cAMP production in human lymphocytes after physical exercise, 142S
GRAF, R. *see* BIRNBAUMER, L.
GRAHAM, B. *see* WALDEN, R.J.
GRAHAM, B.R. *see* TOMLINSON, B.
GRAHAME-SMITH, D.G. *see* BAKES, A.
GRAHAME-SMITH, D.G. *see* WOOD, A.J.
GRAM, L.F. *see* SINDRUP, S.H.
GRAY, S.J. *see* ROLAN, P.E.
GREAVES, M. Platelet function tests in the assessment of antithrombotic agents, 175
GREEN, C.P. *see* SAMPSON, A.P.
GEEN, J.A. *see* KASMER, R.J.
GRIBNAU, F.W.J. *see* VAN MEYEL, J.J.M.
GRODUM, W. *see* SINDRUP, S.H.
GROSS, G. *see* HANET, G.
GROSS, G. *see* KOSINSKI, C.
GROSSE-WILDE, H. *see* VAN TITS, L.J.H.
GROTH, G.G. *see* LINDHOLM. A.
GRUNBERGER, J. *see* SALETU, B.
GUDJONSSON, O., SANZ, E., ALVAN, G., AQUILONIUS, S.-M. & REVIRIEGO, J. Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease, 301
GUILIANI, L. *see* PACIFICI, G.M.
GUTIERREZ, J. *see* FERNANDEZ DE GATTA, M.M.
GUY, S., VERMA, S.P. & SILKE B. Paradoxical actions of cromakalim on systolic and diastolic function in coronary disease, 314P

HAEFELFINGER, P. *see* HARTMANN, D.
HAJDUCKA, C. *see* JEFFREY, R.F.
HALABI, A. *see* HINRICHSEN, H.
HALABI, A., LINDE, M. & KIRCH, W. Differences in haemodynamic effects of nitrendipine and felodipine in patients with congestive heart failure, 342P

HALLIDAY, F. *see* AL-LANQAWI Y.
HAMILTON, C.A. *see* MACGILCHRIST, A.J.
HAMILTON, C.A., YAKUBU, M.A., HOWIE, C.A., JARDINE, E. & REID, J.L. Desensitization and down-regulation of brain α_2-adrenoceptors by centrally acting antihypertensive drugs, 131S
HAMILTON, G. *see* PALMER, A.
HAN, S.-H. *see* WESTFALL, T.C.
HANFT, G. & GROSS, G. The effect of reserpine, desipramine and thyroid hormone on α_{1a}- and α_{1b}-adrenoceptor binding sites: evidence for a subtype-specific regulation, 125S
HANFT, G. *see* KOSINSKI, C.
HANNING, C.D. *see* COLE, L.
HANNING, C.D. *see* RHODES, S.P.
HARDER, S., FUHR, U., BEEMANN, D. & STAIB, A.H. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf capsule, 35
HARDY, E., KUMAR , S., PEAKER, S., FEELY, M. & PULLAR, T. A comparison of a short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone) and measurements of a controlled release 'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete compliance by volunteers, 437
HARDY, E., KUMAR, S., PEAKER, S., FEELY, M. & PULLAR, T. A comparison of a short-life marker, a long half-life indicator and a slow release 'therapeutic' drug for detecting incomplete compliance, 311P
HARNINASUTA, T. *see* NOSTEN, F.
HARPER, P.G. *see* LEWIS, L.D.
HARRIS, B. *see* JONES, C.R.
HARRON, D.W.G. *see* MCKAIGUE, J.P.
HARTMANN, D., KORN, A, KOMJATI, M., HEINZ, G., HAEFELFINGER, P., DEFOIN, R. & WALDHAUSL. W.K. Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide, 245
HARVEY, J. *see* MULLOY, E.M.
HASHIMOTO, K. *see* SUZUKI, E.
HASINOFF, B.B. *see* CAMPBELL, N.R.C.
HAWKEY, C.J. *see* HAWTHORNE, A.B.
HAWTHORNE, A.B., FILIPOWICZ, B.L., EDWARDS, T.J. & HAWKEY, C.J. High dose eicosapentaenoic acid ethyl ester: effects on lipids and neutrophil leukotriene production in normal volunteers, 187
HAYES, Y. *see* TOMLINSON, B.
HECTORS, M.P.C. *see* GRAAFSMA, S.J.
HEIDEMANN, H.T. *see* MONIG, H.
HEINZ, G. *see* HARTMANN, D.
HELSBY, N.A., WARD, S.A., EDWARDS, G., HOWELLS, R.E. & BRECKENRIDGE, A.M. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism, 593
HELSBY, N.A., WARD, S.A., HOWELLS, R.E. & BRECKENRIDGE, A.M. *In vitro* metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme, 287
HENDERSON, A.H. *see* HOGAN, J.C.
HENDERSON, E. *see* MURDOCH, D.L.
HENDRA, T.J. *see* WAGAINE-TWABWE, D.
HENDRY, W. *see* VANDENBURG, M.
HERGUETA, T. *see* BERLIN, I.
HERRICK, A.L. *see* BEVAN, E.G.
HERRSTEDT, J., JORGENSEN, M. & ANGELO, H.R. The effect of food on serum concentrations of metopimazine, 237
HIEBLE, J.P., EDEN, R.J. & DE MEY, C. The role of DA_1- and DA_2-receptors in the control of blood pressure, 61S
HINRICHSEN, H., HALABI, A., HUBNER, G. & KIRCH, W. Haemodynamic effects of various histamine H_2-receptor antagonists assessed by non-invasive techniques, 305P
HJEMDAHL, P., LARSSON, K., JOHANSSON, M.-J., ZETTERLUND, A. & EKLUND, A. β-adrenoceptors in human alveolar macrophages isolated by elutriation, 673
HOBART, J. *see* STACHER, G.
HOCHLEITNER, G. *see* BAUMGARTNER, H.
HOGAN, J.C., LEWIS, M.J. & HENDERSON, A.H. Chronic administration of *N*-acetylcysteine fails to prevent nitrate tolerance in patients with stable angina pectoris, 573
HOLGATE, S.T. *see* RAFFERTY, P.
HOLT, B.L. *see* TOON, S.
HONEYMOON *see* NOSTEN, F.
HORTNAGL, H. *see* BAUMGARTNER, H.
HOULGRAVE, R. *see* BACK, D.J.
HOWELLS, R.E. *see* HELSBY, N.A.
HOWIE, C.A. *see* HAMILTON, C.A.
HOYER, D. *see* JONES, C.R.
HRICIK, D. *see* KASMER, R.J.
HUBNER, G. *see* HINRICHSEN, H.
HUGHES, D.M. *see* MACDONALD N.J.
HUUPPONEN, R. *see* KALLIO, J.

IDLE, J.R. *see* CAPORASO, N.
IDLE, J.R. *see* EDWARDS, C.
IISALO, E. *see* KALLIO, J.
INABA, T. *see* JORGE, L.F.
IND, P.W. *see* DIXON, C.M.S.
INGRAND, I. *see* COUET, W.
INSEL, P.A. *see* JASPER, J.R.
IRVINE, N.A. *see* LIPWORTH, B.J.
IRVINE, N.A., LIPWORTH, B.J. & MCDEVITT, D.G. A dose-ranging study to evaluate the β-adrenoceptor selectivity of single doses of betaxolol, 119
ISTIN, B. *see* COUET, W.
IYUN, A.O., TUCKER, G.T., WOODS, H.F. & LENNARD, M.S. The 4-hydroxylation of (s)-mephenytoin in Nigerians: a population study, 312P

JACKSON, L. *see* RAFFERTY, P.
JACKSON, P.R. *see* JORGE, L.F.
JACQZ-AIGRAIN, E., LAURENT, J. & ALVAREZ, F. Dextromethorphan phenotypes in paediatric patients with autoimmune hepatitis, 153
JAKOBS, K.H. *see* REITHMANN, C.
JAMES, O.F.W. *see* WYNNE, H.A.
JANSSEN, M. *see* FOLKERTS, G.
JANSSEN, U. *see* UNSELD, E.
JARDINE, E. *see* HAMILTON, C.A.
JARVIS, R.C. *see* KASMER, R.J.

JASPER, J.R., MICHEL, M.C. & INSEL, P.A. The β-adrenoceptor antagonist carteolol and its metabolite 8-hydroxycarteolol have different intrinsic sympathomimetic activities, 109S
JEFFREY, R.F., CAPEWELL, S., BROWN, J., COLLIER, A., HAJDUCKA, C. & LEE, M.R. Effects of felodipine on atrial natriuretic peptide in hypertensive non-insulin dependent daibetes mellitus, 481
JOHANSSON, M.-J. *see* HJEMDAHL, P.
JOHNSTON, A. *see* SALEH, S.
JONES, C.R., FANDELEUR, P., HARRIS, B. & BUHLER, F.R. Effect of calcium and β-adrenoceptor antagonists on β-adrenoceptor density and $G_{s\alpha}$ expression in human atria, 171S
JONES, C.R., PALACIOS, J.M., HOYER, D. & BUHLER, F.R. Receptor modification in the brains of spontaneously hypertensive and Wistar-Kyoto rats: regionally specific and selective increase in cerebellar α_2-adrenoceptors, 174S
JONES, D.A. *see* TOMLINSON, B.
JORGE, L.F., ARIAS, T.D., INABA, T. & JACKSON, P.R. Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama, 281
JORGENSEN, M. *see* HERRSTEDT, J.
JOUBERT, P.H., VENTER, H.L. & FOUKARIDIS, G.N. The effect of miglitol and acarbose after an oral glucose load; a novel hypoglycaemic mechanism?, 391
JOYCE, D.A. & DAY, R.O. D-penicillamine and D-penicillamine-protein disulphide in plasma and synovial fluid of patients with rheumatoid arthritis, 511
JULIEN, J. *see* WEBER, S.
JUNG, R.T. *see* CONNACHER, A.A.

KAHAN, A. *see* WEBER, S.
KALIX, P. *see* BRENNEISEN, R.
KALLIO, A. *see* KARHUVAARA, S.
KALLIO, J., HUUPPONEN, R., SEPPALA, M., SAKO, E. & IISALO, E. The effects of β-adrenoceptor antagonists and levopromazine on the metabolic ratio of debrisoquine, 638
KARA, M. *see* CAMPBELL, N.R.C.
KARBWANG, J. *see* DAVIS, T.M.E.
KARBWANG, J. *see* NOSTEN, F.
KARHUVAARA, S., KALLIO, A., SCHEININ, M., ANTTILA, M., SALONEN, J.S. & SCHEININ, H. Pharmacological effects and pharmacokinetics of atipamezole, a novel α_2-adrenoceptor antagonist - a randomized, double-blind cross-over study in healthy male volunteers, 97
KASMER, R.J., CUTLER, R.E., MUNGER, M.A., JARVIS, R.C., HRICIK, D., NARA, A.R., GOLDBERG, P. & GREEN, J.A. Single-dose effects of ibopamine hydrochloride on renal function in patients with congestive heart failure, 485
KHAMSSI, M. *see* MOTOMURA, S.
KILDAY, G. *see* SERIES, J.J.
KING, D.J., BELL, P., BEST, S.J. & MANNION, M. A comparison of the effects of chlorpromazine and temazepam on saccadic eye movements and psychomotor performance, 309P
KIRCH, W. *see* HALABI, A.
KIRCH, W. *see* HINRICHSEN, H.
KITTERINGHAM, N.R. *see* RILEY, R.J.
KITTERINGHAM, N.R. *see* ROBERTS, P.
KIVISTO, K.T. & NEUVONEN, P.J. Effect of activated charcoal on frusemide induced diuresis: a human class experiment for medical students, 496
KIVISTO, K.T. & NEUVONEN, P.J. The effect of cholestyramine and activated charcoal on glipizide absorption, 733
KLAASSEN, A.B.M. *see* VAN MEGEN, Y.J.B.
KLOTZ, U. *see* LI, G.
KLOTZ, U. *see* UNSELD, E.
KNUEPFER, M. *see* WESTFALL, T.C.
KOELBING, U. *see* BRENNEISEN, R.
KOMJATI, M. *see* HARTMANN, D.
KORN, A *see* HARTMANN, D.
KOSINSKI, C., GROSS, G. & HANFT, G. Effect of hypo- and hyperthyroidism on binding of [^{3}H]-nitrendipine to myocardial and brain membranes, 128S
KOTRBA, M. *see* UNGER, TH.
KROON, J.M. *see* VAN STEVENINCK, A.L.
KRUPKA, M. *see* SALETU, B.
KUBLER, W. *see* STRASSER, R.H.
KUGI, A. *see* STACHER, G.
KUITUNEN, T., MATTILA, M.J., SEPPALA, T., ARANKO, K. & MATTILA, M.E. Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests, 443
KULKARNI, R.D. *see* DOSHI, B.S.
KUMAR , S. *see* HARDY, E.
KUMAR, S. *see* PULLAR, T.

LACEY, L.F. *see* SCOTT, A.K.
LACOMBLEZ, L. *see* BENSIMON, G.
LAKER, M. *see* SCIBERRAS, D.G.
LAKIE, M. *see* CONNACHER, A.A.
LAMONT, M. *see* TIPLADY, R.
LANG, C.C., CHOY, A.M., GIBB, L.A. & STRUTHERS, A.D. Does the sympathetic nervous system assist or oppose the natriuretic effect of atrial natriuretic factor in man?, 315P
LANG, C.C., COUTIE, W.J., BALFOUR, D.J.K. & STRUTHERS, A.D. Renal effects of neuronally released noradrenaline in man: dose response studies, 334P
LANG, C.C. *see* MCDERMID, G.
LANG, C.C. *see* RAHMAN, A.R.A.
LANG, C.C., RAHMAN, A.R., COUTIE, W.J.K., BALFOUR, D.J.K. & STRUTHERS, A.D. Renal effects of circulating noradrenaline in man: dose-response studies, 335P
LAPORTE, J.-R. *see* MORLANS, M.
LARSSON, K. *see* HJEMDAHL, P.
LATINI, R. *see* CASTEL, J.M.
LAURENT, J. *see* JACQZ-AIGRAIN, E.
LE DINH, T. *see* GENEVE, J.
LECAILLON, J.B., DUBOIS, J.P., SOULA, G., PICHARD, E., POLTERA, A.A. & GINGER, C.D. The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis, 629

LEE, M.R. *see* JEFFREY, R.F.
LEEMAN, A.L. *see* BOWES, S.G.
LEES, K.R. *see* MACDONALD N.J.
LEFEBVRE, R.A., BOGAERT, M.G., TEIRLYNCK, O., SIOUFI, A. & DUBOIS, J.P. Influence of exercise on nitroglycerine plasma concentrations after transdermal application, 292
LEFKOWITZ, R.J. *see* BENOVIC, J.L.
LENNARD, L., LILLEYMAN, J.S., VAN LOON, J. & WEINSHILBOUM, R.M. Childhood acute lymphoblastic leukaemia: pharmacogenic variation in response to 6-mercaptopurine, 324P
LENNARD, M.S., ADAMS, M., OTTON, S.V., TUCKER, G.T. & WOODS, H.F. Species differences in the sensitivity of metoprolol oxidation to inhibition by the quinidine/quinine isomer pair, 323P
LENNARD, M.S. *see* IYUN, A.O.
LENNARD, M.S. *see* OTTON, S.V.
LEOPALDI, D. *see* CASTEL, J.M.
LEWIS, A.D. *see* TOMLINSON, B.
LEWIS, J.D. *see* BRAIN, S.D.
LEWIS, L.D. *see* LEWIS, L.D.
LEWIS, L.D., FITZGERALD, D.L., HARPER, P.G. & ROGERS, H.J. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism, 725
LEWIS, M.J. *see* HOGAN, J.C.
LEWIS, R.V. *see* CURRIE, D.
LI, G., TREIBER, G., MEINSHAUSEN, J., WOLF, J., WERRINGLOER, J. & KLOTZ, U. Is cyclosporin A an inhibitor of drug metabolism?, 71
LILLEYMAN, J.S. *see* LENNARD, L.
LIND, M.J., MARGOSPM, J.M., CERNY, T., THATCHER, N. & WILKINSON, P.M. The effect of age on the pharmacokinetics of ifosfamide, 140
LINDE, M. *see* HALABI, A.
LINDHOLM, A., DAHLQVIST, R., GROTH, G.G. & SJOQVIST, F. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation, 443
LINDSTROM, B. *see* CHOONARA, I.
LIPWORTH, B.J. *see* IRVINE, N.A.
LIPWORTH, B.J., IRVINE, N.A. & MCDEVITT, D.G. A dose-ranging study to evaluate the β-adrenoceptor selectivity of betaxolol, 316P
LIPWORTH, B.J., TREGASKIS, B.F. & MCDEVITT, D.G. Comparison of extrapulmonary β-adrenoceptor responses to inhaled salbutamol and isoprenaline in young and elderly subjects, 327P
LITTLER, W.A. Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard, 871
LIU, J.B. *see* WALDEN, R.J.
LOFT, S. *see* SONNE, J.
LOHSE, M.J. *see* BENOVIC, J.L.
LOOAREESUWAN, S. *see* DAVIS, T.M.E.
LORIMER, A.R. *see* BEVAN, E.G.
LORIMER, A.R. *see* SERIES, J.J.
LUCKE, G. *see* BAUMGARTNER, H.
LUI, J.B. *see* TOMLINSON, B.
LUNDE, P.K.M. *see* MATHESON, I.
LYNN, K.L. *see* BEGG, E.J.
MACDONALD, N.J., HUGHES, D.M., LEES, K.R. & REID, J.L. Pharmacodynamic, pharmacokinetic and humoral effects of oral zabicipril, an angiotensin converting enzyme inhibitor in normotensive man, 107
MACGILCHRIST, A.J., DEIGHTON, N.M., HAMILTON, C.A. & REID, J.L. Binding studies of platelet α_2- and lymphocyte β_2-adrenoceptors in patients with cirrhosis, 644
MACLEAN, D., RAMSAY, L.E. & RICHARDSON, P.J. Enalapril and nifedipine in the treatment of mild to moderate essential hypertension: a 6-month comparison, 203
MAISEL, A.S. & MICHEL, M.C. β-adrenoceptor control of immune function in congestive heart failure, 49S
MAISEL, A.S. *see* MICHEL, M.C.
MAK, M. *see* RAGHOEBAR, M.
MANCHEE, K. *see* EAGLE, S.
MANNION, M. *see* KING, D.J.
MANSIER, P., CHEVALIER, B., MAYOUX, E., CHARLEMAGNE, D., OLLIVIER, L., CALLENS-EL AMRANI, F. & SWYNGHEDAUW, B. Membrane proteins of the myocytes in cardiac overload, 43S
MARASINI, B. & BASSANI, C. Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon, 847
MARGISON, J.M. *see* LIND, M.J.
MARLEY, J.E. *see* MULLOY, E.M.
MARQUETANT, R. *see* STRASSER, R.H.
MARTIN, C. *see* CRAWFORD, P.
MARTIN, J. *see* WESTFALL, T.C.
MARTINEZ, C., GATTI, G., SASSO, E., CALZETTI, S. & PERUCCA, E. The disposition of primidone in elderly patients, 607
MASSART, D.L. *see* VERCRUYSSE, I.
MASSON, G. *see* BLIN, O.
MATHESON, I., LUNDE, P.K.M. & BREDESEN J.E. Midazolam and nitrazepam in the maternity ward: milk concentrations and clinical effects, 787
MATHESON, I., SANDE, H.A. & GAILLOT, J. The excretion of zopiclone into breast milk, 267
MATTERA, R. *see* BIRNBAUMER, L.
MATTILA, M.E. *see* KUITUNEN, T.
MATTILA, M.J. *see* KUITUNEN, T.
MAYOUX, E. *see* MANSIER, P.
MCCAFFERTY, D.F. *see* WOOLFSON, A.D.
MCCLELLAND, G.R., COOPER, S.M. & PILGRIM, A.J. A comparison of the central nervous system effects of haloperidol, chloropromazine and sulpiride in normal volunteers, 795
MCCONNELLY, J.G. *see* PASSMORE, A.P.
MCDERMID, G., LANG, C.C., DORAN, J.F. & STRUTHERS, A.D. Attitudes of physicians towards the treatment of elevated serum cholesterol, 337P
MCDEVITT, D.G. *see* CURRIE, D.
MCDEVITT, D.G. *see* IRVINE, N.A.
MCDEVITT, D.G. *see* LIPWORTH, B.J.
MCDEVITT, D.G. *see* NICHOLSON, A.N.
MCELNAY, J.C. *see* PASSMORE, A.P.
MCEWEN, J. *see* AL-LANQAWI, Y.
MCGRATH, B.P. *see* SILAGY, C.A.
MCINNES, G.T. *see* BEVAN, E.G.

McINNES, G.T. *see* MURDOCH, D.L.
McKAIGUE, J.P. & HARRON, D.W.G. Effect of UK-52,046, an α_1-adrenoceptor antagonist, on baroreflex function in man, 579
McNEIL, J.J. *see* SILAGY, C.A.
MEIJER, S. *see* GIRBES, A.R.J.
MEINEKE, I. *see* EAGLE, S.
MEINSHAUSEN, J. *see* LI, G.
MEREDITH, P.A. *see* DONNELLY, R.
MERKEL, C., BOLOGNESI, M., ANGELI, P., FINUCCI, G.F., AMODIO, P., BELLON, S. & GATTA, A. Lack of effect of verapamil and isosorbide dinitrate on the hepatic clearance of indocyanine green in cirrhosis, 221
MICHEL, M.C. *see* JASPER, J.R.
MICHEL, M.C. *see* MAISEL, A.S.
MICHEL, M.C., MAISEL, A.S. & O.-E. BRODDE Mitigation of β_1- and/or β_2-adrenoceptor function in human heart failure, 37S
MINUZ, P., BARROW, S.E., COCKCROFT, J.R. & RITTER, J.M. Effects of non-steroidal anti-inflammatory drugs on prostacyclin and thromboxane biosynthesis in patients with mild essential hypertension, 519
MITTELBACH-STEINER, G. *see* STACHER, G.
MOLHOLM HANSEN, J. *see* SONNE, J.
MONIG, H., BAESE, C., HEIDEMANN, H.T., OHNHAUS, E.E. & SCHULTE, H.M. Effects of oral contraceptive steroids on the pharmacokinetics of phenprocoumon, 115
MONKMAN, S. *see* EDWARDS, C.
MONTASTRUC, J.L. *see* BAGHERI, H.
MONTASTRUC, P. *see* BAGHERI, H.
MORELAND, T.A. *see* AL-LANQAWI, Y.
MORGAN, D.J., CAMPBELL, G.A. & CRANKSHAW, D.P. Pharmacokinetics of propofol when given by intravenous infusion, 144
MORLANS, M., LAPORTE, J.-R., VIDAL, X., CABEZA, D. & STOLLEY, P.D. End-stage renal disease and non-narcotic analgesics: a case-control study, 717
MORLEY, M.J., BRADSHAW, C.M. & SZABADI, E. Effects of clonidine and yohimbine on the pupillary light reflex in healthy volunteers, 308P
MORSELLI, P.L. *see* WEBER, S.
MOTOMURA, S., DEIGHTON, N.M., ZERKOWSKI, H.-R., KHAMSSI, M. & BRODDE, O.-E. Differential regulation of human cardiac β-adrenergic and muscarinic receptors by chronic β-adrenoceptor antagonist treatment, 112S
MOTWANI, J. *see* RAHMAN, A.R.A.
MOTWANI, J.G. & STRUTHERS, A.D. Redistribution of blood flow by angiotensin II in man: a dose response study, 336P
MULLER, T.H., SU, C.A.P.F., WEISENBERGER, H., BRICKL, R., NEHMIZ, G. & EISERT, W.G. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood *ex vivo*, 179
MULLINS, F.G.P. *see* TOON, S.
MULLOY, E.M., CORMIE, P., HARVEY, J. & MARLEY, J.E. Nitrendipine therapy in asthmatic subjects, 493
MUNGER, M.A. *see* KASMER, R.J.
MURDOCH, D.L., HENDERSON, E., DARGIE, H.J. & McINNES, G.T. Acute effects of cicletanine in angina pectoris, 341P
MURISS, S. *see* PALMER, A.
MURRAY, G.D. *see* BEVAN, E.G.
MUSCH, B. *see* SALETU, B.
MUSCH, G. *see* VERCRUYSSE, I.

NA BBANGCHANG, K. *see* NOSTGEN, F.
NAES, L. *see* WESTFALL, T.C.
NAHORSKI, S.R. Receptors, inositol polyphosphates and intracellular Ca^{2+}, 23
NALINE, E., SARRIA, B., ERTZBISCHOFF, O., OZANNE, P. & ADVENIER, C. Comparative β-adrenoceptor blocking effects of propranolol, bisoprolol, atenolol, acebutolol and diacetolol on the human isolated bronchus, 135
NARA, A.R. *see* KASMER, R.J.
NEHMIZ, G. *see* MULLER, T.H.
NELIGAN, M. *see* BORTON, M.
NEUMAYER, H.-H. *see* FRITSCHKA, E.
NEUVONEN, P.J. *see* KIVISTO, K.T.
NG, W.H., POLOSA, R. & CHURCH, M.K. Adenosine bronchoconstriction in asthma: investigations into its possible mechanism of action, 89S
NICHOLSON, A.N. *see* CURRIE, D.
NICHOLSON, A.N., WRIGHT, N.A., ZETLEIN, M.B., CURRIE, D. & McDEVITT, D.G. Central effects of the angiotensin-converting enzyme inhibitor, captopril. II. Electroencephalogram and body sway, 537
NICHOLSON, P.W. *see* BOWES, S.G.
NICHOLSON, P.W. *see* CHEUNG, R.
NIELSEN, J.C., BJERRING, P., ARENDT-NIELSEN, L. & PETTERSON, K.-J. A double-blind, placebo controlled, cross-over comparison of the analgesic effect of ibuprofen 400 mg and 800 mg on laser-induced pain, 711
NIJKAMP, F.P. *see* FOLKERTS, G.
NIJKAMP, F.P. *see* GARSSEN, J.
NIJKAMP, F.P. *see* VAN HEUVEN-NOLSEN, D.
NIJKAMP, F.P. *see* VAN OOSTERHOUT, A.J.M.
NOORMOHAMED, F.H. Use of E_{max} model in diuretic studies, 943
NOROTA, I. *see* ENDOH, M.
NOSTEN, F., KARBWANG, J., WHITE, N.J., HONEYMOOON, NA BANGCHANG, K., BUNNAG, D. & HARNINASUTA, T. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study, 79
NWOKOLO, C.U. & POUNDER, R.E. D-penicillamine does not increase urinary bismuth excretion in patients treated with tripotassium dicitrato bismuthate, 648

O'NEILL, C.J.A. *see* BOWES, S.G.
O'NEILL, C.J.A. *see* CHEUNG, R.
OGG, G.D. & STEVENSON, I.H. 1-2-3-4. One step beyond Lotus 1-2-3 for storing, tabulating and summarising pharmacokinetic data, 342P
OHNHAUS, E.E. *see* MONIG, H.
OOKABE, K. *see* BIRNBAUMER, L.
OLIVE, G. *see* REY, E.
OLLIVIER, L. *see* MANSIER, P.

OLSON, S.C. *see* BEGG, E.J.
ONORATO, J. *see* BENOVIC, J.L.
ORME, M. *see* BACK, D.J.
ORME, M. *see* CRAWFORD, P.
OSTMAN, J. *see* DAHL-PUUSTINEN, M.-L.
OTOMO, J. *see* ENDOH, M.
OTTON, S.V., GILLAM, E.M.J., LENNARD, M.S., TUCKER, G.T. & WOODS, H.F. Propranolol oxidation by human liver microsomes — the use of cumene hydroperoxide to probe iso-enzyme specificity and regio- and stereoselectivity, 751
OTTON, S.V. *see* LENNARD, M.S.
OZANNE, P. *see* NALINE, E.

PACIFICI, G.M., VIANI, A., FRACHI, M., SANTERINI, S., TEMELLINI, A., GUILIANI, L. & CARRAI, M. Conjugation pathways in liver disease, 427
PACKARD, C.J. *see* SERIES, J.J.
PAGE, C.P. The role of platelet activating factor in allergic respiratory disease, 99S
PALACIOS, J.M. *see* JONES, C.R.
PALMER, A., FLETCHER, A., HAMILTON, G., MURISS, S. & BULPITT, C. A comparison of verapamil and nifedipine on quality of life, 365
PARK, B.K. *see* COLEMAN, M.D.
PARK, B.K. *see* RILEY, R.J.
PARK, B.K. *see* ROBERTS, P.
PARK, B.K. *see* TINGLE, M.D.
PARKER, J.E. *see* ROLAN, P.E.
PARRY, P. *see* RHODES, S.P.
PASSMORE, A.P., MCELNAY, J.C., CRAWFORD, V.L.S., MCCONNELLY, J.G., TAYLOR, I.C. & WALKER, F.S. Indomethacin - pharmacokinetic profile and renal effects after chronic dosing in elderly patients and young volunteers, 325P
PAYAN, C. *see* BERLIN, I.
PEACOCK, J.E. *see* REILLY, C.S.
PEAKER, S. *see* HARDY, E.
PEAKER, S. *see* PULLAR, T.
PERUCCA, E. *see* MARTINEZ, C.
PETTERSON, K.-J. *see* NIELSEN, J.C.
PETTY, R.G. *see* BRAIN, S.D.
PFLEIDERER, S. *see* WOODCOCK, B.G.
PHILLIP, Th. *see* FRITSCHKA, E.
PHILLIPS, S.C. *see* ROLAN, P.E.
PICHARD, E. *see* LECAILLON, J.B.
PIEHL, J. *see* WOODCOCK, B.G.
PILGRIM, A.J. *see* MCCLELLAND, G.R.
PINQUIER, J.L. *see* WEBER, S.
PIPER, P.J. *see* SAMPSON, A.P.
PISTORIUS, M.C.M. *see* RAGHOEBAR, M.
POLOSA, R. *see* NG, W.H.
POLTERA, A.A. *see* LECAILLON, J.B.
PONS, G. *see* REY, E.
POSNER, J. *see* ROLAN, P.E.
POTTER, C. *see* WIGHT, L.
POTTER, C., DEWS, I., PULLAN, T., WIGHT, L. & VANDENBURG, M. Morning *vs* evening dosing of sustained-release verapamil in mild to moderate hypertension, 338P
POUNDER, R.E. *see* NWOKOLO, C.U.
POWERS, N. *see* CONNACHER, A.A.
PRICE, J.F. *see* SAMPSON, A.P.
PRICHARD, B.N.C. *see* TOMLINSON, B.
PRICHARD, B.N.C. *see* WALDEN, R.J.
PRINGLE, S.D. *see* BEVAN, E.G.
PUECH, A.J. *see* BERLIN, I.
PULLAN, T. *see* POTTER, C.
PULLAN, T. *see* WIGHT, L.
PULLAR, T. Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today ortoday's treatment tomorrow?, 501
PULLAR, T. *see* HARDY, E.
PULLAR, T., KUMAR, S., PEAKER, S. & FEELY, M. Patterns of compliance in hypertension, 318P

QADRI, F. *see* UNGER, TH.
QUINLAN, D. *see* WEBB, A.J.
QUINN, K. *see* COLE, L.

RAFFERTY, P., JACKSON, L., SMITH, R. & HOLGATE, S.T. Terfenadine, a potent histamine H_1-receptor antagonist in the treatment of grass pollen sensitive asthma, 229
RAGHOEBAR, M., MAK, M., COURNOT, A., PISTORIUS, M.C.M., VAN HARTEN, J. & ROSEBOOM, H. Pharmacokinetics of eltoprazine in healthy male subjects after single dose oral and intravenous administration, 879
RAHMAN, A.R. *see* LANG, C.C.
RAHMAN, A.R.A., MOTWANI, J., LANG, C.C. & STRUTHERS, A.D. The interaction between atrial natriuretic peptide (ANF99-126) and aldosterone on renal sodium handling in man, 318
RAMSAY, L.E. *see* FOSTER, G.
RAMSAY, L.E. *see* MACLEAN, D.
RAMSEY, L.E. *see* YEO, W.W.
RANE, A. *see* CEDERHOLM, I.
RANE, A. *see* CHOONARA, I.
RANKINE, D. *see* CAMPBELL, N.R.C.
RASHID, M.U. & BATEMAN, D.N. Effect of intravenous atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers, 25
RAWLINS, M.D. *see* EDWARDS, C.
RAWLINS, M.D. *see* WYNNEE, H.A.
REED, J. *see* SCIBERRAS, D.G.
REID, J.L. *see* BEVAN, E.G.
REID, J.L. *see* BRODDE, O.-E.
REID, J.L. *see* DONNELLY, R.
REID, J.L. *see* HAMILTON, C.A.
REID, J.L. *see* MACDONALD N.J.
REID, J.L. *see* MACGILCHRIST, A.J.
REID, J.L. *see* SCHAFERS, R.F.
REIFART, N. *see* WOODCOCK, B.G.
REILLY, C.S., GILL, S.S. & PEACOCK, J.E. Infusion rate as determinant in induction of anaesthesia, 334P
REITBROCK, N. *see* WOODCOCK, B.G.
REITHMANN, C., GIERSCHIK, P., WERDAN, K. & JAKOBS, K.H. Hormonal regulation of $G_{i\alpha}$ level and adenylyl cyclase responsiveness, 118S
REITSMA, W.D. *see* GIRBES, A.R.J.
RENONDIN, J.C. *see* TOMLINSON, B.
RETTIG, R. *see* UNGER, TH.
REVIRIEGO, J. *see* GUDJONSSON, O.
REY, E., PONS, G., RICHARD, M.O., VAUZELLE, F., D'ATHIS, Ph., CHIRON, C., DULAC, O., BEAUMONT,

D. & OLIVE, G. Pharmacokinetics of the individual enantiomers of vigabatrin (γ-vinyl GABA) in epileptic children, 253
REY, F. *see* FERNANDEZ DE GATTA, M.M.
RHODES, S.P., PARRY, P. & HANNING, C.D. A comparison of the effects of zolpidem and placebo on respiration and oxygen saturation during sleep in the healthy elderly, 817
RICHARD, M.O. *see* REY, E.
RICHARDSON, P.J. *see* MACLEAN, D.
RIECKMANN, K.H. *see* EDSTEIN, M.D.
RIETBROCK, N. *see* WOODCOCK, B.G.
RILEY, R.J., ROBERTS, P., COLEMAN, M.D., KITTERINGHAM, N.R. & PARK, B.K. Bioactivation of dapsone to a cytotoxic metabolite: *in vitro* use of a novel two compartment system which contains human tissues, 417
RITTER, J.M. *see* MINUZ, P.
ROBERTS, C.J.C. *see* FORSYTH, D.R.
ROBERTS, P. *see* RILEY, R.J.
ROBERTS, P., KITTERINGHAM, N.R. & PARK, B.K. Species difference in the *in vitro* bioactivation of mianserin, 322P
ROBERTSON, S. *see* COLE, L.
ROBIN, L. *see* BERLIN, I.
ROBINSON, P. *see* VANDENBURG, M.
ROBSON, R.A. *see* BEGG, E.J.
RODEN, D.M. *see* FUNCK-BRENTANO, C.
RODRIGUES DE MIRANDA, J.F. *see* GRAAFSMAN, S.J.
RODRIGUES DE MIRANDA, J.F. *see* VAN MEGEN, Y.J.B.
ROGERS, H.J. *see* LEWIS, L.D.
ROHMESS, P. *see* UNGER, TH.
ROLAN, P.E., PHILLIPS, S.C., GRAY, S.J., PARKER, J.E., ADAMS, J. & POSNER, J. The onset of the effect of H_2-receptor antagonist acrivastine assessed by histamine bronchial challenge in volunteers, 326P
ROSEBOOM, H. *see* RAGHOEBAR, M.
ROSENZWEIG, P. *see* WEBER, S.
ROUTLEDGE, P.A. *see* AL-SHAREEF, A.
ROWLAND, M. *see* TOON, S.
RUMP, L.C., SCHUSTER, M.J., WILDE , K. & SCHOLLMEYER, P. Modulation of noradrenaline release from rat cortical kidney slices: effects of angiotensin I and II, 168S
RUMP, L.C., WILDE, K. & SCHOLLMEYER, P. Prostaglandin E_2 inhibits and indomethacin enhances noradrenaline release in isolated kidneys of adult spontaneously hypertensive rats, 165S

SAGER, G. Effects of insulin on human β-adrenoceptors, 139S
SAKO, E. *see* KALLIO, J.
SALEH, S., JOHNSTON, A. & TURNER, P. Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans, 621
SALETU, B., FREY, R., GRUNBERGER, J., KRUPKA, M., ANDERER, P. & MUSCH, B. Sleep laboratory studies on single dose effects of suriclone, 703
SALONEN, J.S. *see* KARHUVAARA, S.
SAMPSON, A.P., SPENCER, D.A., GREEN, C.P., PIPER, P.J. & PRICE, J.F. Leukotrienes in the sputum and urine of cystic fibrosis children, 861
SANDE, H.A. *see* MATHESON, I.
SANTERINI, S. *see* PACIFICI, G.M.
SANZ, E. *see* GUDJONSSON, O.
SARRIA, B. *see* NALINE, E.
SASSO, E. *see* MARTINEZ, C.
SCHAFERS, R.F., ELLIOTT, H.L. & REID, J.L. An evaluation of the α-adrenoceptor antagonism produced by SK&F 86466 in healthy normotensive males, 884
SCHEININ, H. *see* KARHUVAARA, S.
SCHNEIDER, C. *see* STACHER, G.
SCHOEMAKER, H.C. *see* VAN STEVENINCK, A.L.
SCHOLLMEYER, P. *see* RUMP, L.C.
SCHOORS, D.F. & DUPONT, A.G. Lithium and the natriuretic response to gludopa, fenoldopam and dopamine, 651
SCHOORS, D.F. *see* VERCRUYSSE, I.
SCHULTE, H.M. *see* MONIG, H.
SCHUSTER, M.J. *see* RUMP, L.C.
SCIBERRAS, D. *see* WARREN, J.B.
SCIBERRAS, D.G., REID, J., ELLIOTT, C., LAKER, M. & GOLDBERG, M.R. A study of the effect of MK-467 on the metabolic responses to exercise in healthy man, 307P
SCOTT, A.K. *see* COLEMAN, M.D.
SCOTT, A.K., WALLEY, T., BRECKENRIDGE, A.M., LACEY, L.F. & FOWLER, P.A. Lack of effect of propranolol on sumatriptan pharmacokinetics, 332P
SCOTT, D.B. *see* TIPLADY, R.
SCOTT, R.A., WOODS, K.L. & BARNETT, D.B. The effects of flosequinan on regional blood flow in normal man, 317P
SEDDIGHI, S. *see* FRITSCHKA, E.
SEGRESTAA, J.M. *see* GENEVE, J.
SELF, T.H. *see* THOMPSON, J.R.
SEPPALA, M. *see* KALLIO, J.
SEPPALA, T. *see* KUITUNEN, T.
SERIES, J.J., GAW, A., KILDAY, G., BEDFORD, D.K., LORIMER, A.R., PACKARD, C.J. & SHEPHERD, J. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia, 49
SERRATRICE, G. *see* BLIN, O.
SHELDON, T.A. A graphical presentation of the results of crossover trials, 345
SHEPHERD, J. *see* SERIES, J.J.
SHETTY, H.G.M. *see* AL-SHAREEF, A.
SILAGY, C.A., MCNEIL, J.J., FARISH, S. & MCGRATH, B.P. A comparison of dilevalol and placebo in the management of isolated systolic hypertension using ambulatory monitoring, 657
SILBERSTEIN, D.J. *see* FUNCK-BRENTANO, C.
SILKE, B. *see* GUY, S.
SIM, S.M. & BACK, D.J. Glucuronidation of zidovudine (azidothymidine) by human liver microsomes, 321P
SIMON, P. *see* BENSIMON, G.
SINCLAIR, A.J., DAVIES, I.B. & WARRINGTON, S.J. Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin, 699
SINDRUP, S.H., GRAM, L.F., SKJOLD, T., GRODUM, W., BROSEN, K. & BECK-NIELSEN, H. Clomipramine *vs* desipramine *vs* placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study, 683

SIOUFI, A. *see* LEFEBVRE, R.A.
SJOQVIST, F. *see* LINDHOLM. A.
SKJOLD, T. *see* SINDRUP, S.H.
SMIT, A.J. *see* GIRBES, A.R.J.
SMITH, C. *see* WALDEN, R.J.
SMITH, C.C.T. *see* WAGAINE-TWABWE, D.
SMITH, R. *see* RAFFERTY, P.
SMITH, S.E. *see* THOMAS, S.H.L.
SMITS, P. *see* VAN MEYEL, J.J.M.
SONNE, J., BOESGAARD, S., ENGHUSEN POULSEN, H., LOFT, S., MOLHOLM HANSEN, J., DOSSING, M. & ANDREASEN, F. Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism, 737
SOULA, G. *see* LECAILLON, J.B.
SPENCER, D.A. *see* SAMPSON, A.P.
STACHER, G., BERGMANN, H., GAUPMANN, G., SCHNEIDER, C., KUGI, A., HOBART, J., BINDER, A. & MITTELBACH-STEINER, G. Fat preload delays gastric emptying: reversal by cisapride, 839
STACHER, G., BERGMANN, H., SCHNEIDER, C., STEINER-MITTELBACH, G., GAUPMANN, G., STEINRINGER, H., ABATZI, Th.-A. & STACHER-JANOTTA, G. Effects of 5-HT_3 receptor antagonist ICS 205-930 on fat-delayed gastric emptying and antral motor activity, 41
STACHER-JANOTTA, G. *see* STACHER, G.
STAIB, A.H. *see* HARDER, S.
STANISZEWSKI, C. *see* BENOVIC, J.L.
STEINER-MITTELBACH, G. *see* STACHER, G.
STEINRINGER, H. *see* STACHER, G.
STEPHENS, J. *see* VANDENBURG, M.
STEVENSON, I.H. *see* AL-LANQAWI, Y.
STEVENSON, I.H. *see* OGG, G.D.
STOLLEY, P.D. *see* MORLANS, M.
STRASSER, R.H., MARQUETANT, R. & KUBLER, W. Independent sensitization of β-adrenoceptors and adenylate cyclase in acute myocardial ischaemia, 27S
STRAUCH, G. *see* WEBER, S.
STRIESSENIG, J. *see* BAUMGARTNER, H.
STRUTHERS, A.D. *see* LANG, C.C.
STRUTHERS, A.D. *see* MCDERMID, G.
STRUTHERS, A.D. *see* MOTWANI, J.G.
STRUTHERS, A.D. *see* RAHMAN, A.R.A.
SU, C.A.P.F. *see* MULLER, T.H.
SUMMERS, L.A. *see* DOBBS, N.A.
SUTTON, J.A. *see* BOYLE, R.
SUZUKI, E., TSUJIMOTO, G. & HASHIMOTO, K. Different desensitization mechanisms of two α_1-adrenoceptor subtypes in the contraction of rabbit aorta, 121S
SWYNGHEDAUW, B. *see* MANSIER, P.
SZABADI, E. *see* MORLEY, M.J.

TAMAYO, M. *see* FERNANDEZ DE GATTA, M.M.
TAYLOR, I.C. *see* PASSMORE, A.P.
TEIRLYNCK, O. *see* LEFEBVRE, R.A.
TEMELLINI, A. *see* PACIFICI, G.M.
TEN HAVE, G.A.M. *see* VAN HEUVEN-NOLSEN, D.
THATCHER, N. *see* LIND, M.J.
THEIN, TH. *see* GRAAFSMA, S.J.
THIEDE, H.-M. *see* BERLIN, I.
THIEDE, H.-M. *see* FRITSCHKA, E.
THIERCELIN, J.F. *see* BENSIMON, G.
THOMAS, S.H.L. & SMITH, S.E. Systolic time intervals by the impedance method: accuracy and correlations with left ventricular function, 304P
THOMPSON, J.R. & SELF, T.H. Theophylline and isoniazid, 909
THUNBERG, E. *see* DAHL-PUUSTINEN, M.-L.
THURMANN, P. *see* WOODCOCK, B.G.
TIJA, J. *see* CRAWFORD, P.
TIJA, J.F. *see* BACK, D.J.
TIJA, J.F., WEBBER, I.R. & BACK, D.J. Metabolism of cyclosporin by human gastrointestinal mucosa *in vitro*, 320P
TINGLE, M.D., COLEMAN, M.D. & PARK, B.K. An investigation of the role of metabolism in dapsone-induced methaemoglobinaemia using a two compartment *in vitro* test system, 829
TIPLADY, R., FAGAN, D., LAMONT, M., BROCKWAY, M. & SCOTT, D.B. A comparison of the CNS effects of enprofylline and theophylline in healthy subjects assessed by performance testing and subjective measures, 55
TOMLINSON, B., CUICKSHANK, J.M., HAYES, Y., RENONDIN, J.C., LUI, J.B., GRAHAM, B.R., JONES, D.A., LEWIS, A.D. & PRICHARD, B.N.C. Selective β-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects, 665
TOMLINSON, B. *see* WALDEN, R.J.
TOON, S., HOLT, B.L., MULLINS, F.G.P., BULLINGHAM, R., AARONS, L. & ROWLAND, M. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin, 743
TREGASKIS, B.F. *see* LIPWORTH, B.J.
TREIBER, G. *see* LI, G.
TSUJIMOTO, G. *see* SUZUKI, E.
TUCKER, G.T. *see* IYUN, A.O.
TUCKER, G.T. *see* LENNARD, M.S.
TUCKER, G.T. *see* OTTON, S.V.
TURNER, P. *see* SALEH, S.
TURNER, R.C. *see* DAVIS, T.M.E.
TWELVES, C.J. *see* DOBBS, N.A.

UNGER, TH., BADOER, E., GAREIS, C., GIRCHEV, R., KOTRBA, M., QADRI, F., RETTIG, R. & ROHMESS, P. Atrial natriuretic peptide (ANP) as a neuropeptide: interaction with angiotensin II on volume control and renal sodium handling, 83S
UNSELD, E., ZIEGLER, G., GEMEINHARDT, A., JANSSEN, U. & KLOTZ, U. Possible interaction of fluoroquinolones with the benzodiazepine-$GABA_A$-receptor complex, 63

VAN BRUMMELEN, P. *see* VAN ZWIETEN, P.A.
VAN DER VLEIT, H. *see* GARSSEN, J.
VAN HARTEN, J. *see* RAGHOEBAR, M.
VAN HEUVEN-NOLSEN, D., TEN HAVE, G.A.M. & NIJKAMP, F.P. Neutrophils increase histamine contractions in pig coronary artery: a role for lipoxygenase products, 156S
VAN LOON, J. *see* LENNARD, I.
VAN LOVEREN, H. *see* GARSSEN, J.

VAN MEGEN, Y.J.B., RODRIGUES DE MIRANDA, J.F. & KLAASSEN, A.B.M. Alterations of neuroreceptors in nasal hyperreactivity, 162S

VAN MEYEL, J.J.M., SMITS, P. & GRIBNAU, F.W.J. Absence of magnesium sparing effect of a single dose of triamterene in combination with frusemide in healthy male adults, 714

VAN OOSTERHOUT, A.J.M. & NIJKAMP, F.P. Effect of lymphokines on β-adrenoceptor function of human peripheral blood mononuclear cells, 150S

VAN STEVENINCK, A.L., VERVER, S., KROON, J.M., SCHOEMAKER, H.C., BREIMER, D.D. & COHEN, A.F. Relationships between plasma concentration of temazepam and effects of saccadic peak velocity in individual subjects, 310P

VAN TITS, L.J.H., DAUL, A., GROSSE-WILDE, H. & BRODDE, O.-E. Cyclic AMP antagonizes mitogen-induced accumulation of inositol phosphates in human peripheral mononuclear leucocytes in vitro, 148S

VAN TITS, L.J.H. *see* GRAAFSMA, S.J.

VAN ZWIETEN, P.A. *see* BRODDE, O.-E.

VAN ZWIETEN, P.A., BLAUW, G.J. & VAN BRUMMELEN, P. The role of 5-hydroxytryptamine and 5-hydroxytryptaminergic mechanisms in hypertension, 69S

VANDENBURG, M., DEWS, I., GIBBS, J., HENDRY, W., ROBINSON, P. & STEPHENS, J. Sustained release verapamil in chronic stable angina pectoris: a multicentre randomized double-blind crossover-design trial *vs* placebo, 340P

VANDENBERG, M.J. *see* FOALE, R.A.

VANDENBURG, M. *see* POTTER, C.

VANDENBURG, M. *see* WIGHT, L.

VANDONGEN, A.M.J. *see* BIRNBAUMER, L.

VAUZELLE, F. *see* REY, E.

VEENENDALL, J.R. *see* EDSTEIN, M.D.

VENTER, H.L. *see* JOUBERT, P.H.

VERCRUYSSE, I., SCHOORS, D.F., MUSCH, G., MASSART, D.L. & DUPONT, A.G. Nicardipine does not influence the pharmacodynamics of atenolol, 499

VERMA, S.P. *see* GUY, S.

VERVER, S. *see* VAN STEVENINCK, A.L.

VIANI, A. *see* PACIFICI, G.M.

VIDAL, X. *see* MORLANS, M.

WAGAINE-TWABWE, D., HENDRA, T.J., SMITH, C.C.T. & YUDKIN, J.S. The effects of dopexamine, a new dopamine anologue, on platelet function in stress, 87

WALDEN, R.J., TOMLINSON, B., GRAHAM, B., PRICHARD, B.N.C. & LIU, J.B. Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers, 557

WALDEN, R.J., TOMLINSON, B., GRAHAM, B., SMITH, C., BETTERIDGE, D.J. & PRICHARD, B.N.C. Withdrawal phenomena after atenolol and bopindolol; hormonal changes in normal volunteers, 547

WALDHAUSL. W.K. *see* HARTMANN, D.

WALKER, F.S. *see* PASSMORE, A.P.

WALLE, T. & WALLE, U.K. Stereoselective sulphate conjugation of racemic terbutaline by human liver cytosol, 127

WALLE, U.K. *see* WALLE, T.

WALLER, D.G. β-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?, 157

WALLER, P.C. *see* BEVAN, E.G.

WALLEY, T. *see* SCOTT, A.K.

WALSH, E.G. *see* CONNACHER, A.A.

WARD, S.A. *see* HELSBY, N.A.

WAROT, D. *see* BENSIMON, G.

WARREN, J.B., DOLLERY, C.T., SCIBERRAS, D. & GOLDBERG, M. Assessment of MK-467, a peripheral α_2-adrenoceptor antagonist using intravenous clonidine, 306P

WARRINGTON, S.J. *see* SINCLAIR, A.J.

WEBB, A.J., AL-AZAWIE, D.M., DAVIES, B.E., COOPER, S.M., QUINLAN, D. & ARNOLD, B.D.C. The effects of co-administration of food or antacid on the pharmacokinetics of renzapride, 329P

WEBBER, I.R. *see* TIJA, J.F.

WEBER,S., KAHAN, A., PINQUIER, J.L., JULIEN, J., ROSENZWEIG, P., BIANCHETTI, G., MORSELLI, P.L., DESSAULT, O., DE LAUTURE, D. & STRAUCH, G. Pharmacodynamic without pharmacokinetic interaction between cicloprolol, a partial β_1-adrenoceptor agonist, and digoxin in healthy subjects, 411

WEINSHILBOUM, R.M. *see* LENNARD, I.

WEISENBERGER, H. *see* MULLER, T.H.

WELLER, C. *see* BOWES, S.G.

WERDAN, K. *see* REITHMANN, C.

WERRINGLOER, J. *see* LI, G.

WESTFALL, T.C., HAN, S.-H., KNUEPFER, M., MARTIN, J., CHEN, X., DEL VALLE, K., CIARLEGLIO, A. & NAES, L. Neuropeptides in hypertension: role of neuropeptide Y and calcitonin gene related peptide, 75S

WHITE, N.J. *see* DAVIS, T.M.E.

WHITE, N.J. *see* NOSTEN, F.

WIEDERMANN, C.J. *see* BAUMGARTNER, H.

WIGHT, L. *see* POTTER, C.

WIGHT, L., VANDENBURG, M., POTTER, C. & PULLAN, T. A double-blind general practice based comparative study of sustained release verapamil with atenolol in patients with mild to moderate hypertension, 339P

WIKSTROM, I. *see* DAHL-PUUSTINEN, M.-L.

WILDE , K. *see* RUMP, L.C.

WILKINSON, G.R. *see* DOSHI, B.S.

WILKINSON, G.R. *see* ZHOU, H.H.

WILKINSON, P.M. *see* LIND, M.J.

WILLEMS, P.H.G.M. *see* GRAAFSMA, S.J.

WILLIAMS, T.J. *see* BRAIN, S.D.

WOLF, J. *see* LI, G.

WOOD, A.J., BREARLEY, C.J., ARONSON, J.K. & GRAHAME-SMITH, D.G. The effect of oral salbutamol on cation transport measured *in vivo* in healthy volunteers, 383

WOOD, A.J.J. *see* FUNCK-BRENTANO, C.

WOOD, A.J.J. *see* ZHOU, H.H.

WOOD, F. *see* BORTON, M.

WOODCOCK, B.G., PFLEIDERER, S., THURMANN, P., RIETBROCK, N., GIOKOGLU, K. & REIFART, N. Prolonged anti-ischaemic action of nifedipine administered as fatty-acid alcohol matrix tablets to patients with coronary artery disease, 328P

WOODCOCK, B.G., PIEHL, J. & RIETBROCK, N. Verapamil serum protein binding properties: quantification and classification, 330P
WOODHOUSE, K.W. *see* WYNNE, H.A.
WOODS, H.F. *see* IYUN, A.O.
WOODS, H.F. *see* LENNARD, M.S.
WOODS, H.F. *see* OTTON, S.V.
WOODS, K.L. *see* SCOTT, R.A.
WOOLFSON, A.D., MCCAFFERTY, D.F. & BOSTON, V. Clinical experiences with a novel percutaneous amethocaine preparation: prevention of pain due to venepuncture in children, 273
WOOSLEY, R.L. *see* FUNCK-BRENTANO, C.
WRIGHT, N.A. *see* CURRIE, D.
WRIGHT, N.A. *see* NICHOLSON, A.N.
WYNNE, H.A., GOUDEVENOS, J., RAWLINS, M.D., JAMES, O.F.W., ADAMS, P.C. & WOODHOUSE, K.W. Hepatic drug clearance: the effect of age using indocyanine green as a model compound, 634
YAKUBU, M.A. *see* HAMILTON, C.A.
YANG, J. & DUNDEE, J.W. A non-invasive approach to P6 anti-emesis in cancer chemotherapy, 307P
YATANI, A. *see* BIRNBAUMER, L.
YEO, W.W. *see* FOSTER, G.
YEO, W.W., FOSTER, G. & RAMSEY, L.E. Prevalence of cough in patients taking enalapril: controlled study *vs* nifedipine, 312P
YUDKIN, J.S. *see* WAGAINE-TWABWE, D.

ZERKOWSKI, H.-R. *see* MOTOMURA, S.
ZETLEIN, M.B. *see* NICHOLSON, A.N.
ZETTERLUND, A. *see* HJEMDAHL, P.
ZHOU, H.H., ANTHONY, L.B., WOOD, A.J.J. & WILKINSON, G.R. Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin, 471
ZIEGLER, G. *see* UNSELD, E.
ZIMMER, R. *see* BERLIN, I.

SUBJECT INDEX

(P = Proceedings; S = Supplement)

α_1-adrenoceptor, 383S
α_1-adrenoceptor antagonist, 115
α_1-adrenoceptor subtype, 579
α_1-adrenoceptor subtypes, 121S, 125S
α_1-adrenoceptor antagonist, 97, 306P, 307P, 884
α_2-adrenoceptors, 131S, 135S
Absorption, 35
Absorption interactions, 733
Acarbose, 391
Acetylsalicylic acid, 179
Acetyltransferase, 427
Acipimox, 49
Acrivastine, 326P
Activated charcoal, 496, 733
Activation, 593
Acupuncture, 307P
Adenosine, 89S
Adenylyl cyclase, 27, 55S, 118S
Adrenaline, 145S, 673
Adrenoceptor, 613
Adrenoceptors, 142S, 162S, 644
Adverse drug reactions, 63
Age, 25, 140, 325P, 327P, 634
Airway hyperreactivity, 153S
Alcohol, 333P
Aldosterone, 318P
Alpha-glucosidase inhibitors, 391
Alveolar macrophages, 673
Ambulatory monitoring, 657
Amethocaine, 273
Amiloride, 319P
Amocarzine, 625, 629
Amphetamine-like, 825
Anaesthesia, 334P
Analgesia, 711, 318P
Analgesics, 717
ANF 99–126, 318P
Angina, 573
Angina pectoris, 313P, 340P, 341P
Angiotensin, 83S 168S
Angiotensin II, 336P
Angiotensin converting enzyme inhibitor, 107
Antacid, 329P
Antiarrhythmic, 155
Antidepressant, 621
Antiemetics, 237
Antihistamine, 229
Antimalarial prophylaxis, 79
Antithrombotic agents, 175
Antral motor activity, 41, 839
Anxiety, 377
Apomorphine, 769
Aspirin, 717
Asthma, 89S, 229, 493
Atenolol, 195, 339P, 499
Atipamezole, 97
Atrial natriuretic factor, 83S, 315P, 318P
Atropine, 25
Audiometry, 1
Autonomic function, 25
Awakening quality, 703
Azidothymidine, 321P
AZT, 321P

β-adrenoceptor, 109S, 119S, 150S, 157
β-adrenoceptor antagonist, 316P
β-adrenoceptor antagonists, 171S, 638
β-adrenoceptor blocker, 557
β-adrenoceptor blockers, 135, 547
β-adrenoceptors, 275, 43S, 49S, 55S, 139S, 673
β_1- and β_2-adrenoceptors in the human heart, 112S
β_1-adrenoceptor, 37S
β_1-adrenoceptor partial agonist, 411
β_2-adrenoceptors, 37S, 145S, 174S, 195
BN 52063, 99
BRL 26830A, 613
Baroreflex function, 579
Benzodiazepine-GABA-receptor complex, 63
Benzodiazepines, 63, 311P
Betaxolol, 119, 316P, 699
Biguanides, 287
Bioavailability, 328, 331P, 621, 629, 634
Bismuth intoxication, 648
Blinking, 769
Blood, 511
Blood flow, 317P, 336P, 853
Blood pressure, 61S, 83S, 107, 519
Body position, 292
Body sway, 537
Brain, 83S
Breast milk, 267, 787
Breast-feeding, 267
Bronchial hyperreactivity, 159S
Broncho-alveolar cells, 159S
Bronchoconstriction, 371
Burns, 901

CGP 6140, 625, 629
CGRP, 853
Ca^{++}-channels, 128S
Ca^{2+} homeostasis, 23
Calcitonin gene related peptide, 75S
Calcium antagonist, 481, 871
Calcium channel blockers, 365
Calcium signalling, 121S
Cancer chemotherapy, 307P

Cancer risk, 149
Captopril, 305P, 527, 537
Carbamazepine, 453, 892
Carbidopa, 13
Cardiac insufficiency, 43S
Cardiac reticulum, 43S
Cardioselectivity, 119
Carteolol, 109S
Catecholamines, 275, 135S, 337P
Cathinone, 825
Cerebellum, 174S
Charcoal, 331P
Children, 153, 897, 901
Chiral pharmacology, 253
Chlorpromazine, 309P, 795
Cholesterol, 337P
Cholestyramine, 49, 733
Chronic β-adrenoceptor antagonist treatment, 112S
Cicletidine, 341P
Cicloprolol, 411
Cimetidine, 761
Ciprofloxacin, 35
Cirrhosis, 644
Cisapride, 839
Clinical tests, 453
Clinical trial, 345
Clomipramine, 683
Clonidine, 131S, 306P, 308P
Co-trimoxazole, 889
Complex formation, 599
Compliance, 311P, 318P, 437
Congestive heart failure, 342P, 485
Coronary artery disease, 328P
Coronary disease, 314P
Cough, 312P, 327P
Creatine kinase, 665
Creatinine clearance, 485
Cromakalim, 314P
Crossover trial, 345
Cumene hydroperoxide, 751
Cuna Amerindians, 281
Cyclic AMP, 139S, 142S, 148S, 150S, 151S, 673
Cyclosporin, 320P, 443
Cyclosporin A, 71
Cystic fibrosis, 861
Cytochrome P450, 417
Cytochrome P-450IID6, 751

D-penicillamine, 511, 648
DA_1-receptor, 61S
DA_2-receptor, 61S
Dapsone, 259, 417, 761, 829
Debrisoquine, 301, 638, 653
Debrisoquine biotransformation, 281
Debrisoquine polymorphism, 476
Densensitization, 3S
Densitization, 27S, 121S
Dependent diabetes mellitus, 481
Desipramine, 125S, 683
Dextromethorphan, 153
Diabetic neuropathy, 683
Digoxin, 411
Dilevalol, 657
Dipyridamole, 179
Diuretics, 907P
Dopamine, 61S, 87, 651, 652, 769
Dopexamine, 87
Drug extraction, 634
Drug interaction, 889
Drug interactions, 71, 115, 616
Drug metabolism, 71
Drug monitoring, 443
Drug toxicity, 417
Drug–drug interaction, 743

EEG, 795
Editorial, 175, 351
Efficacy, 203
5,8,11,14,17-eicosapentaenoic acid, 187
Elderly, 13, 607
Electroencephalogram, 537
Eltoprazine, 879
Elutriation, 673
E_{max} models, 907
Enalapril, 203, 297, 312P
Enantiomer, 195
Enprofylline, 55
Enuresis, 693
Enzyme induction, 892
Enzyme inhibition, 638
Epidemiology, 149
Epidoxorubicin, 324P
Epigastric impedance, 405
Epileptic children, 253
Erythrocyte, 383
Erythropoietin, 135S
Essential hypertension, 383
Ethinyloestradiol, 321P, 892
Exercise, 292, 307P
Experimental pain, 711

Fat-delayed, 41
Fat-delayed gastric emptying, 839
Felodipine, 324P, 481, 567, 871
Fenoldopam, 651, 652
Ferrous sulphate, 599
Flosequinan, 317P
Flunitrazepam, 463
Fluorescence polarization immunoassay, 443
Fluoroquinolones, 63
Food, 237, 329P, 629
Frusemide, 496, 714

G-protein, 13S, 27S
Gait, 13
Gastric emptying, 25, 41, 405
Gastrointestinal binding, 496
Gastrointestinal mucosa, 320P
Genetic polymorphism, 312P, 471, 779
Gentamicin, 1
Glibenclamide, 245, 476, 699
Glipizide, 733
Glucuronidation, 115
Glucuronyltransferase, 427
Glucose, 397, 699
Glucose intolerance, 245
Gludopa, 651, 652
Glutathione transferase, 427

Glyceryl trinitrate, 573
Guanabenz, 131S
Guanine nucleotide-binding protein, 118S

H_1-receptor antagonist, 326P
H_2-receptor antagonists, 305P
Haematological variables, 743
Haemodialysis, 135S
Haemodynamic responses, 557
Haloperidol, 795
Healthy volunteers, 463
Heart cells, 118S
Heart failure, 37S, 49S
Heart rate, 195, 490
Hepatitis, autoimmune, 153
hf-capsule, 27
High pressure liquid chromatography, 443
Hills-Armitage, 345
Histamine, 156S, 305P
Histamine reactivity, 493
Homoeopathy, 173
Hormonal changes, 547
5-HT_1-receptor agonist, 332P
5-HT-receptors, 107S
5-HT_3 receptor agonist, 41
Human bronchus, 135
Human coronary artery, 107S
Human gastrointestinal tract, 35
Human liver, 127
Human liver microsomes, 287
Human performance, 453
Human saphenous vein, 107S
Human sleep, 703
Hydralazine, 305P
Hydrogel suppository, 781
5-hydroxytryptamine, 69S, 107S, 847
Hyperlipidaemia, 49
Hypertension, 55S, 69S, 75S, 135S, 165S, 174S, 203, 305P, 314P, 318P, 338P, 339P, 351, 353, 519, 567, 871
Hypnotic, 817
Hypnotic effect, 787
Hypnotics, 463
Hypothyroidism, 737

Ibopamine, 485
Ibuprofen, 711
ICG kinetics, 297
ICS-205–930, 41
Ifosfamide, 140, 725
Imipramine, 693
Immune system, 49S
Impedance method, 304P
Indocyanine green, 221, 634
Indomethacin, 325P
Induction agent, 334P
Induction of metabolism, 471
Infusion rate, 334P
Inhibition, 761
Inhibitors, 3S
Inositol phosphates, 23S, 148S
Inotropic effect, 115S
Insulin, 139S, 397, 699
Interaction, 155, 245, 318P, 471
Intrinsic sympathomimetic activity, 109S
[^{125}I]-iodopindolol, 673
Isolated systolic hypertension, 657
Isoniazid, 311P, 437, 909
Isoprenaline, 135, 327P, 673, 327

K^+ channels, 13S
Ketamine, 901
Ketanserin, 847
Ketorolac, 743
Khat, 825
Kidney, 165, 168
Kidney failure, chronic, 717
Kinases, 3S
Kinetics, 259, 607

Laboratory tests, 453
Lacrimal secretion, 151
Laser stimulation, 711
Left ventricular function, 304P, 411
Leukotrienes, 861
Leukotrienes B, 187
Levodopa, 13, 599
Levomepromazine, 638
Levonorgestrel, 892
Lightreflex, 377
Linear regression model, 490
Lipoproteins, 49, 187
Lipoxygenase products, 156S
Lithium, 651, 652
Liver blood flow, 634
Liver cirrhosis, 221
Liver disease, 427
Liver metabolism, 221
Liver microsomes, 321P, 322P, 323P
Lorazepam, 703
Lotus 1–2–3–4, 342P
Lung cancer, 149, 653
Lymphoblastic leukaemia, 324P
Lymphocyte β_2, 644
Lymphocytes, 49S
Lymphokines, 150S

MK-467, 306P, 307P
Macrolides, 616
Magnesium, 714
Malaria, 259
Maloprim, 259
Man, 761
Mania, 383
Medifoxamine, 621
Mefloquine, 79
Mephenytoin, 287, 471, 779
Mephenytoin polymorphism, 476
6-mercaptopurine, 324P
Metabolic responses, 307P
Metabolism, 35, 607, 751, 829
Metformin, 699
Methaemoglobinaemia, 829
Metopimazine, 237
Metoprolol, 311P, 323P, 437
Mianserin, 322P
Microsomes, 71
Midazolam, 71, 787

Miglitol, 391
Migraine, 405
Milk fat, 787
Milk pH, 787
Moclobemide, 805
Monoamine metabolites, 805
Mononuclear cells, 150S
Mononuclear leucocytes, 148S
Mood, 527
Morphine, 781, 897, 901
Multiple sleep latency test, 463
Muscarinic M_2-receptors in the human heart, 112S
Muscarinic receptors, 43S, 162S
Myocardial hypertrophy, 128S
Myocardial ischaemia, 27S

N-acetylcysteine, 573
N-hydroxylation, 761
NSAID, 519
Na^+,K^+-ATPase, 43S, 383
Nasal hyperreactivity, 162S
Natriuresis, 585
Natriuretic response, 651
Nedocromil sodium, 371
Neonates, 897
Nephritis, interstitial, 717
Neuropeptides, 75S
Neutrophils, 156S
Nicardipine, 499
Nicoumalone, 616
Nifedipine, 171S, 203, 305P, 312P, 313P, 328P, 331P, 365, 871, 889
Nitrazepam, 787
Nitrendipine, 128S, 342P, 493, 585
Non-insulin, 481
Noradrenaline, 118S, 334P, 335P
Noradrenaline reactivity, 135S
Noradrenaline release, 165S, 168S
Normal volunteers, 547, 557

Obesity, 613
Onchocerca volvulus, 625, 629
Oral anticoagulants, 616
Oral contraceptive steroids, 115
Oral hypoglycaemia agents, 391
Ototoxicity, 1
Oxazepam, 737
Oxidative metabolism, 281

P6 anti-emesis, 307P
PR interval, 490
Paediatrics, 273
Paracetamol, 25, 737
Parainfluenza type 3 virus, 159S
Parkinson's disease, 301, 599
Parkinsonism, 13
Partial agonist activity, 665
Partial agonists, 157
Patients, 625, 629
Percutaneous anaesthesia, 273
Performance, 527
Pharmacodynamic, 743
Pharmacodynamics, 97, 213, 499, 737
Pharmaco-EEG, 63
Pharmacokinetics, 79, 97, 115, 140, 144, 213, 253, 267, 325P, 329P, 331P, 342P, 453, 476, 499, 616, 621, 625, 725, 737, 743, 879, 889
Phenobarbitone, 311P, 437
Phenotype, 301, 312P, 653
Phenprocoumon, 115
Phenylephrine, 579
Phenytoin, 892
Phorbol-12,13-dibutyrate, 115S
Phosphorylation, 3S
Pindolol, 665
Plasma ANP, 481
Plasma concentration, 711
Plasma nitroglycerin, 292
Plasma protein binding, 787
Platelet activating factor, 99S
Platelet aggregates, 179
Platelet aggregation, 847
Platelet function tests, 175
Platelet α_2, 644
Platelets, 87
Ponsinomycin, 616
Portal hypertension, 221
Prazosin, 579
Pregnancy, 79
Prejunctional receptors, 165S, 168S
Prenalterol, 127
Presbyacusis, 1
Pressor responses, 884
Primidone, 607
Progestogens, 321P
Proguanil, 593
Propafenone, 155
Propofol, 144
Propranolol, 171S, 332P, 751
Prostacyclin, 519
Prostaglandin E_1, 673
Prostaglandins, 165S, 585
Protein binding, 330P, 511
Psychometric performance, 805
Psychometry, 703
Psychomotor performance, 55, 309P, 463, 795
Pupil, 377
Pupillary light reflex, 308P
Pyrazolones, 717
Pyrimethamine, 259

Quality of life, 351, 353, 365
Quinapril, 213
Quinaprilat, 213
Quinidine, 323P, 397
Quinine, 323P, 397

Rabbit aorta, 121S
Radioimmunoassay, 443
Raynaud's, 853
Raynaud's phenomenon, 847
Reactive hyperaemia, 853
Receptor density, 174S
Receptor regulation, 125S
Receptors, 3S, 23S
Renal effects, 334P, 335P
Renal impairment, 213
Renal insufficiency, 485

Renal plasma flow, 485
Renal transplantation, 443
Renin-aldosterone, 107
Renzapride, 329P
Reserpine, 125S
Residual effect, 463
Respiration, 817
Reversible MAO inhibitor, 805
Review, 157, 353, 501
Rheumatoid arthritis, 501, 511
Rifampicin, 155, 471
Rilmenidine, 131S
Rubidium, 35

S-mephenytoin, 301, 312P
SK&F 86466, 884
Saccadic eye movements, 309P
Saccadic peak velocity, 310P
Safety, 203
Salbutamol, 327P, 383
Salt excretion, 83S
Sarcoplasmic reticulum, 43S
Screening, 1
Sedation, 311P
Sedative-hypnotic properties, 703
Selectivity, 316P
Semisolid meal, 41, 839
Sensitization, 27S
Serenics, 879
Serum concentrations, 237, 693
Sinemet, 599
Sleep, 817
Sleep apnoea, 817
Sodium, 55S
Sodium cromoglycate, 371
Sodium metabisulphite, 371
Sodium valproate, 331P
Somnopolygraphy, 703
Sotalol, 171S, 195
Spironolactone, 319P
Spontaneously hypertensive rats, 128S
Sputum, 861
Stereoselective sulphation, 127
Stress, 87
Sulindac, 327P
Sulphotransferase, 427
Sulphate conjugation, 127
Sulphation, 897
Sulpiride, 795
Sumatriptan, 332P
Suriclone, 703
Synovial fluid, 511
Systolic time intervals, 304P

T-cells, 153S
Teaching, 496
Temazepam, 309P, 310P
Tenoxicam, 245
Terbutaline, 127
Terfenadine, 229
Theophylline, 55, 909
Thermogenesis, 613
Thiomethyltransferase, 427
Thromboxane, 519
Thyroid hormone, 125S, 128S
Tolerability, 203
Tolerance, 573
Toloxatone, 805
Tracheal spiral, 159S
Tremor, 613
Triamterene, 714
Tripotassium dicitrato bismuthate, 648
Type IV hypersensitivity (DTH), 153S

US–52,046, 579
Unimodal distribution, 281
Up-regulation, 142S, 145S
Urine, 861

Variability, 593
Vasodepressor syncope, 337P
Venepuncture, 273
Verapamil, 313P, 330P, 338P, 339P, 340P, 365
Vigabatrin enantiomers, 253
Vigilance, 55
Visual analogue scales, 55

Warfarin, (R)-, (S)-, 743
Whole blood, 179
Withdrawal phenomena, 547, 557

Xamoterol, 665

Yawning, 769
Yohimbine, 151, 308P

Zabicipril, 107
Zidovudine, 321P
Zolpidem, 463, 817
Zopiclone, 267, 453